RT Journal Article
SR Electronic
T1 Quantitative Susceptibility Mapping Radiomics with Label Noise Compensation for Predicting Deep Brain Stimulation Outcomes in Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.26.24319663
DO 10.1101/2024.12.26.24319663
A1 Roberts, Alexandra G.
A1 Zhang, Jinwei
A1 Tozlu, Ceren
A1 Romano, Dominick
A1 Akkus, Sema
A1 Kim, Heejong
A1 Sabuncu, Mert R.
A1 Spincemaille, Pascal
A1 Li, Jianqi
A1 Wang, Yi
A1 Wu, Xi
A1 Kopell, Brian H.
YR 2024
UL http://medrxiv.org/content/early/2024/12/29/2024.12.26.24319663.abstract
AB Parkinson’s disease patients with motor complications are often considered for deep brain stimulation (DBS) surgery. DBS candidate selection involves an assessment known as the levodopa challenge test (LCT). The LCT aims to predict DBS outcomes by measuring symptom improvement accompanying changes in levodopa dosage. While used in the patient selection process, inconsistent LCT predictions have been widely documented, verified here with Pearson’s correlation r = 0.12. Estimating symptom improvement to separate DBS responders and non-responders remains an unmet need. Quantitative susceptibility mapping (QSM) is routinely acquired for pre-surgical planning and depicts the iron distribution in substantia nigra and subthalamic nuclei. Iron deposition in these nuclei has correlated with disease progression and motor symptom severity. A novel QSM radiomic approach is presented using a regression model and features extracted from the pre-surgical targeting acquisition. Noise compensation in training labels improves outcome prediction in regression and classification models. The model predicts improvement in the unified Parkinson’s disease rating scale (UPDRS-III) (r = 0.75). Predictive feature maps in deep gray nuclei offer contrast between responders and non-responders. The QSM radiomic approach has potential to improve DBS candidate selection by accurately estimating symptom improvement, eliminating difficult medication manipulation, and avoiding time-consuming evaluations to reduce patient and clinician burden.Competing Interest StatementPascal Spincemaille and Yi Wang are co-inventors on QSM-related patents owned by Cornell University and have ownership shares in MedImageMetric LLC. The remaining authors have no conflicts of interest to report.Funding StatementThis research was supported by grants from the National Institutes of Health R01 NS095562 and National Multiple Sclerosis Society TA-2204-39428 and FG-2008-36976.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Boards of Weill Cornell Medicine and Mount Sinai and Changhai Hospitals gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes